FIH studies generate the earliest human safety and feasibility data and frequently inform IDE submissions. Many FIH studies are conducted under EU CIPs or in OUS jurisdictions like Australia, Latin America, or New Zealand. FIH studies usually enroll a small number of subjects under close monitoring, with strict stopping rules and careful site selection. Their nonclinical package typically includes bench, animal and biocompatibility testing. FDA accepts data from studies outside the US if they follow good clinical practice under 21 CFR 812.28, which matters when early data from OUS sites is used to support a US IDE.

Why it matters

Choice of FIH geography is a strategic decision balancing cost, IRB/EC speed, follow-up reliability, and FDA's view of the resulting evidence.

Common pitfalls

•A common pitfall is failing to establish clear go/no-go criteria before initiating an FIH study, leading to prolonged or inconclusive trials.
•Another mistake is underestimating the complexity of patient recruitment and retention in early-stage studies.
•Inadequate consideration of global regulatory acceptance of FIH data can lead to difficulties in leveraging study results for multiple market approvals.
•Failing to implement robust data collection and management systems from the outset can compromise data integrity and regulatory submission quality.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.